BDBM524650 (R)-4-(6-(4-(2-(3-chlorophenyl)-2-(dimethylamino)acetyl)piperazin-1-yl)pyridin-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine-3-carbonitrile (Ex. 94) and (S)-4-(6-(4-(2-(3-chlorophenyl)-2-(dimethylamino)acetyl)piperazin-1-yl)pyridin-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine-3-carbonitrile (Ex. 95)::US11168090, Example 94::US11168090, Example 95::US11851434, Example 95

SMILES CN(C)[C@@H](C(=O)N1CCN(CC1)c1ccc(cn1)-c1nc(cn2ncc(C#N)c12)-c1cnn(C)c1)c1cccc(Cl)c1

InChI Key InChIKey=CQVNRLODZUQMSQ-UHFFFAOYSA-N

Data  8 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 8 hits for monomerid = 524650   

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM524650(US11168090, Example 95 | (R)-4-(6-(4-(2-(3-chlorop...)
Affinity DataIC50: 6.5nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
Go to US Patent

LigandPNGBDBM524650(US11168090, Example 95 | (R)-4-(6-(4-(2-(3-chlorop...)
Affinity DataIC50: 13.7nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM524650(US11168090, Example 95 | (R)-4-(6-(4-(2-(3-chlorop...)
Affinity DataIC50: 25.9nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
Go to US Patent

LigandPNGBDBM524650(US11168090, Example 95 | (R)-4-(6-(4-(2-(3-chlorop...)
Affinity DataIC50: 152nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM524650(US11168090, Example 95 | (R)-4-(6-(4-(2-(3-chlorop...)
Affinity DataIC50: 6.5nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/15/2024
Entry Details
Go to US Patent

LigandPNGBDBM524650(US11168090, Example 95 | (R)-4-(6-(4-(2-(3-chlorop...)
Affinity DataIC50: 13.7nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/15/2024
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM524650(US11168090, Example 95 | (R)-4-(6-(4-(2-(3-chlorop...)
Affinity DataIC50: 25.9nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/15/2024
Entry Details
Go to US Patent

LigandPNGBDBM524650(US11168090, Example 95 | (R)-4-(6-(4-(2-(3-chlorop...)
Affinity DataIC50: 152nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/15/2024
Entry Details
Go to US Patent